Topical hair loss treatment, formulated to act where it's applied.
Topical formulations let you target the scalp directly while limiting systemic exposure. The active ingredients — minoxidil for follicular blood flow, finasteride or dutasteride for DHT blockade, plus supporting actives like caffeine, melatonin, ketoconazole, and cetirizine — are absorbed at the application site and act on the same biology of androgenetic alopecia that the oral medications do, with a different side-effect profile.
Obsidian Genetics offers two compounded topical formulations: a 4-active solution (minoxidil 5% / finasteride 0.5% / caffeine 0.2% / melatonin 0.1%) and a more advanced 6-active solution (minoxidil 5% / dutasteride 0.3% / cetirizine 1% / ketoconazole 2% / caffeine 0.2% / melatonin 0.1%). Your provider matches the formulation to your hair-loss pattern, prior response, and tolerance.
Both compounds are prepared by a licensed compounding pharmacy and prescribed by a licensed provider following clinical review. Applied once daily to the scalp.
Topical Hair Loss
Topical hair loss treatment, by the numbers.
Topical minoxidil is FDA-approved. Topical finasteride is well-studied off-label. Each supporting active in our compounded solutions has its own peer-reviewed rationale.
Individual results vary. Topical formulations reduce systemic absorption substantially compared to oral, but absorption still occurs and contraindications still apply. These are compounded prescription products prepared by a licensed compounding pharmacy. The 4-active and 6-active blends are not FDA-approved as combined finished products; each is prescribed off-label by a licensed provider following clinical review.
Two mechanisms. One biology of hair loss. Better together.
DHT Blockade
Finasteride inhibits Type II 5-alpha reductase, the enzyme that converts testosterone to DHT. In androgenetic alopecia, DHT binds to receptors in genetically susceptible hair follicles, triggering miniaturization. Reducing scalp DHT by approximately 64% (Drake 1999) substantially blunts this hormonal driver of hair loss.
Vasodilation & Follicular Circulation
Minoxidil is a potassium channel opener that dilates blood vessels around hair follicles. It increases oxygen and nutrient delivery to the hair bulb, extending the anagen (active growth) phase of the hair cycle. Better blood flow means better fueling of the follicle.
Synergistic Dual Action
Finasteride stops the hormonal damage; minoxidil simultaneously stimulates regrowth and prolongs the growth phase. Used together, they address both cause and consequence of androgenic alopecia far more effectively than either alone.
What patients use this combination for.
Topical Multi-Active vs. Oral vs. Single Topical.
Topical formulations limit systemic exposure. Multi-active formulations layer mechanisms. Here's how the options compare.
What to expect month by month.
Months 1–3
Both mechanisms activate. DHT suppression begins immediately; minoxidil stimulation begins within days. Many patients experience temporary shedding in weeks 2-4; this is normal and reflects the transition of old hairs out of the cycle. Do not stop treatment during this phase.
Months 3–6
Shedding phase resolves. Hair density stabilizes as new growth begins to mature. DHT suppression is now well-established (approximately 64% scalp DHT reduction, per Drake 1999). Circulation improvements are supporting new follicle activity. Subtle improvements may become noticeable by month 5-6.
Months 6–9
Measurable improvement in hair count and density. New hairs are thicker and more pigmented. Hairline may appear fuller; crown density improving. Most patients report noticeable results by month 6-9 of consistent daily use. Improvements continue to compound through month 12.
Month 12+
Full response achieved. Continued daily use maintains results. Hair loss stops; density plateaus at maximum improvement. To maintain these gains, consistent use is required indefinitely. Missing doses or stopping treatment results in gradual loss of benefit.
Safety and what to monitor.
Topical formulations limit systemic exposure substantially compared to oral, but absorption still occurs and contraindications still apply. Here is what to know.
⚠ Important Safety Information
Topical finasteride / dutasteride: Even applied topically, some systemic absorption occurs. Patients with a history of prostate cancer or significantly elevated PSA, and any patient who has previously experienced sexual side effects on oral 5α-reductase inhibitors, should disclose this during intake. Pregnancy / fetal exposure: Pregnant women must not handle these solutions; topical 5α-reductase inhibitors can cause feminization of male fetuses. Wash hands thoroughly after each application and avoid skin-to-skin scalp contact with anyone pregnant or trying to become pregnant. Topical minoxidil: Do not apply to broken or irritated skin. Avoid getting solution in eyes; rinse thoroughly if contact occurs. Patients with uncontrolled cardiovascular disease should discuss before use; while topical absorption is much lower than oral, it is not zero. Ketoconazole: Local irritation, dryness, or transient hair texture changes can occur. Cetirizine topical: May cause mild local stinging or scalp irritation. Drug interactions: Disclose all medications during intake. For men only: These topical formulations are not recommended for women — finasteride/dutasteride exposure risk to potential pregnancies is the limiting factor.
Which topical formulation is right for you?
Both options are compounded prescription topicals applied once daily. The 4-active is a strong first-line topical; the 6-active layers in additional mechanisms for patients seeking more aggressive intervention. Your provider will confirm the right fit during intake.
Topical 4-Active
Minoxidil 5% / Finasteride 0.5% / Caffeine 0.2% / Melatonin 0.1%
What it is: A once-daily compounded topical solution combining FDA-approved minoxidil 5% (vasodilation, follicular blood flow) with topical finasteride 0.5% (DHT blockade), plus two supporting actives — caffeine for additional follicular stimulation and melatonin for antioxidant scalp support.
Best for:
- First-time topical users
- Men who can’t tolerate oral finasteride (sexual side effects, etc.)
- Patients wanting solid first-line topical with two supporting actives
- Early-to-moderate AGA
Why pick this: Topical finasteride reduces scalp DHT comparably to oral 1mg with substantially lower systemic absorption (Caserini 2014). Caffeine 0.2% was non-inferior to topical minoxidil 5% in male AGA (Dhurat 2017). A clean, evidence-based first-line topical.
Topical 6-Active (Advanced)
Min 5% / Dut 0.3% / Cetirizine DihCl 1% / Ketoconazole 2% / Caffeine 0.2% / Melatonin 0.1%
What it is: A more aggressive once-daily compounded topical that swaps finasteride for dutasteride (a more potent dual 5α-reductase inhibitor) and adds ketoconazole 2% (anti-inflammatory/antifungal with AGA evidence) and cetirizine DihCl 1% (antihistamine with hair-related research interest), on top of the same minoxidil + caffeine + melatonin base.
Best for:
Why pick this: Layered, multi-mechanism topical. Dutasteride blocks both Type I and Type II 5α-reductase isoenzymes (vs finasteride's Type II only). Ketoconazole has supportive AGA evidence (Fields 2020). The most comprehensive topical option in our catalog.
Minoxidil 5% — Potassium channel opener / vasodilator. Improves follicular blood flow and prolongs anagen. FDA-approved for AGA.
Finasteride 0.5% — Type II 5α-reductase inhibitor. Reduces scalp DHT (~64% with oral 1mg; topical achieves comparable scalp effect with lower systemic). Caserini 2014 / Hu 2022.
Dutasteride 0.3% — Dual Type I & Type II 5α-reductase inhibitor. More potent DHT suppression than finasteride. Used in the advanced 6-active formula.
Caffeine 0.2% — Penetration enhancer and follicular stimulant. In a head-to-head trial (Dhurat 2017) topical caffeine 0.2% was non-inferior to topical minoxidil 5% in male AGA.
Melatonin 0.1% — Antioxidant with scalp-specific receptors. Topical 0.1% melatonin RCT showed improvement in androgenetic alopecia (Fischer 2004).
Ketoconazole 2% — Anti-inflammatory and antifungal with AGA evidence (Fields 2020 systematic review). Helps when scalp inflammation contributes to hair loss.
Cetirizine DihCl 1% — Topical antihistamine with research interest in AGA via prostaglandin D2 modulation. Included in the advanced 6-active formulation as a complementary mechanism.
All options include: physician consultation · compounded medication · ongoing provider support · free shipping. Not sure which is right? Your Obsidian Genetics provider will discuss your hair-loss pattern, prior treatment history, and tolerance during intake to confirm the best match. For oral hair-loss options (Finasteride 1mg, Min+Fin combo tablet, Fin/Min/Biotin combo capsule), see the Oral Hair Loss page.
Frequently asked question
What's the difference between the 4-active and 6-active topical?
The 4-active is minoxidil 5% + finasteride 0.5% + caffeine 0.2% + melatonin 0.1%. The 6-active swaps finasteride for the more potent dual 5α-reductase inhibitor dutasteride at 0.3%, and adds cetirizine DihCl 1% (an antihistamine with hair-related research interest) and ketoconazole 2% (anti-inflammatory and antifungal with AGA evidence). The 6-active is intended for patients seeking layered topical action, particularly those who haven’t responded fully to single-active or simpler topical regimens. Your provider matches the formulation to your hair-loss pattern, prior response, and tolerance.
Why topical instead of oral finasteride?
Topical finasteride reduces scalp DHT comparably to oral 1mg dosing while producing substantially lower systemic finasteride levels (Caserini et al. 2014). For patients concerned about systemic exposure or who have experienced sexual side effects on oral finasteride, topical can be a meaningful alternative. The Phase III RCT by Hu et al. 2022 found topical finasteride spray non-inferior to oral 1mg for hair count improvement. Discuss with your provider whether topical or oral is the better fit for your situation.
Will I still get sexual side effects from a topical 5α-reductase inhibitor?
Less likely, but not impossible. Topical absorption is much lower than oral, and clinical data show substantially reduced systemic finasteride/dutasteride levels with topical formulations. That said, some systemic exposure occurs, and a small minority of patients still report sexual side effects on topical 5αRI. If you’ve previously experienced sexual side effects on oral finasteride, disclose this during intake — your provider may recommend the 4-active (lower 5αRI dose) or a non-5αRI approach.
How do I apply it?
Once daily to clean, dry scalp — typically the thinning areas. Wash hands thoroughly after application. Allow to dry before going to bed to avoid transferring solution to your pillow or partner. Avoid getting solution in your eyes; rinse with water if it happens. Pregnant women should not handle the product. Specific instructions are provided with each prescription.
How long before I see results?
Like all hair-loss treatments, results build gradually. Initial shedding is normal in the first 4–8 weeks as the hair cycle synchronizes — do not discontinue. Stabilization of loss is typical by month 3–4. Visible regrowth is usually noticeable by month 6, with continued gains through month 12. Consistent daily application is required. If you don’t see improvement by month 6, talk to your provider about adjusting the formulation.
Is this a lifelong commitment?
Yes — for sustained results. As with oral finasteride and topical minoxidil, the underlying biology of androgenetic alopecia continues regardless of treatment. If you stop, the gains are gradually lost as DHT activity and follicular miniaturization resume. Many men view daily topical application as a long-term investment in hair preservation; the routine becomes simple after the first few weeks.
Important: The 4-active and 6-active topical solutions described on this page are compounded preparations. Topical minoxidil 5% is FDA-approved for androgenetic alopecia. The other actives (finasteride, dutasteride, caffeine, melatonin, ketoconazole, cetirizine) are FDA-approved or generally recognized as safe for various indications, but the combined topical formulations are prepared by a licensed compounding pharmacy and are not FDA-approved as finished drug products. Compounded medications are prescribed off-label and their effectiveness has not been independently verified by the FDA. Pregnant women must not handle these products. For men only — topical 5α-reductase inhibitors carry fetal exposure risk. Cited research reflects published clinical studies of the individual actives or related compounded formulations. Prescription required. Individual results vary. All Obsidian Genetics prescriptions are issued following clinical review by a licensed provider. © 2024 Obsidian Genetics. All rights reserved.